Synthon announces European approvals for Eplerenone
Synthon announced that it has successfully concluded multiple registration procedures for the cardiovascular drug Eplerenone. Synthon has obtained regulatory clearance for the product in nine European countries, for both 25 and 50 mg film coated tablets.
Synthon's Eplerenone is a fully generic and bioequivalent version of Pfizer’s Inspra® tablets.
European sales of Eplerenone were 109 million Euros (MAT June 2011) based on IMS Midas data. Synthon’s Eplerenone is part of a rich pipeline of research projects and pending regulatory applications.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.